Research Funding

NCSAR Pilot Grant Program

Deadline:  Friday, July 28, 2017

The NCSAR pilot grant is designed to support innovative pre-clinical translational and clinical research projects to improve investigation, diagnosis and treatment of substance abuse related disorders.

This first request for applications focuses on substance abuse and its consequences on the biological functioning within the CNS, with the ultimate goal of developing therapeutic strategies aimed at preventing and treating drug addiction and the associates co-morbidities.

Information on this opportunity can be found on the NCSAR website

Questions may be directed to:

Shilpa Buch, Ph.D.
NCSAR Director
University of Nebraska Medical Center
402-559-3165

Sara Dejano
Office Assistant to Dr. Buch
University of Nebraska Medical Center
402-559-9523

DoD Spinal Core Injury Research Program

FY17 SCIRP Program Announcements and General Application Instructions for the following award mechanisms are posted on Grants.gov.

As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency (DHA), J9 Research and Development Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation.  The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP).

 

Clinical Research Development Award – Preproposal due August 8, 2017

Independent investigators at all academic levels (or equivalent)

  • Preproposal is required; application submission is by invitation only.
  • Fund research that will establish the necessary collaborations and develop the necessary research resources that will serve as a foundation for investigator-initiated clinical research.
  • Clinical trials not allowed.
  • Maximum funding of $100,000 for direct costs (plus indirect costs)
  • Maximum period of performance is year

 

Clinical Trial Award – Preproposal due August 8, 2017

Independent investigators at all academic levels (or equivalent)

  • Preproposal is required; application submission is by invitation only.
  • Fund Phase 0, I, or II clinical trials with the potential to have a major impact on treatment or management of spinal cord injury (SCI) and its consequences.
  • Preclinical data required for all clinical trial applications.
  • Maximum funding of $2,000,000 for direct costs (plus indirect costs)
  • Maximum period of performance is years

 

Investigator-Initiated Research Award – Preproposal due August 8, 2017

Independent investigators at all academic levels (or equivalent)

  • Preproposal is required; application submission is by invitation only.
  • Fund SCI-related research that has the potential to make an important contribution to SCI research and/or patient care.
  • Preliminary data required.
  • Clinical trials not allowed.
  • Maximum funding of $500,000 for direct costs (plus indirect costs)
  • Maximum period of performance is 3 years

 

Qualitative Research Award – Preapplication due August 8, 2017

Independent investigators at all academic levels (or equivalent)

  • Preproposal is required; application submission is by invitation only.
  • Fund qualitative research on military Service members and Veterans in the years following SCI.
  • Qualitative research is defined as a form of social inquiry that focuses on understanding the way that people interpret and make sense of their experiences and the world in which they live (i.e., seek to understand the human experience).
  • Preliminary data encouraged, but not required.
  • Clinical trials not allowed.
  • Maximum funding of $500,000 for direct costs (plus indirect costs)
  • Maximum period of performance is years

Translational Research Award – Preproposal due August 8, 2017

Independent investigators at all academic levels (or equivalent)

  • Preproposal is required; application submission is by invitation only.
  • Fund studies that accelerate the movement of promising ideas in SCI research into clinical applications.
  • Optional Feature:  Applications that include a Qualified Collaborator that meets criteria identified in the announcement may apply for a higher level of funding.
  • Preliminary data required.
  • Limited clinical testing of a novel intervention or device is permissible.
  • Maximum funding of $1,250,000 for direct costs (plus indirect costs)
  • Maximum funding of $1,500,000 for direct costs (plus indirect costs) for applications including an Optional Qualified Collaborator
  • Maximum period of performance is years

A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline. All applications must conform to the final Program Announcements and General Application Instructions available for electronic downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism will also be found on Grants.gov.  A listing of all CDMRP funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420.

 

Applications must be submitted through the Federal Government’s single-entry portal, Grants.gov.  For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.  For more information about the SCIRP or other CDMRP-administered programs, please visit the CDMRP website (http://cdmrp.army.mil).

Point of Contact:

CDMRP Help Desk
301-682-5507
help@eBrap.org

DOD Neurofibromatosis Research Program

The FY17 Defense Appropriations Act provides $15 million (M) to the Department of Defense NFRP to support innovative, high-impact NF research.  Applications to the FY17 NFRP are being solicited by the U.S. Army Medical Research Acquisition Activity (USAMRAA). The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP).

FY17 NFRP Program Announcements and General Application Instructions for the following award mechanisms are posted on the Grants.gov website.

Areas of Emphasis:  The NFRP encourages applications that specifically address the critical needs of the NF community in one or more of the FY17 Areas of Emphasis.  Not all Areas of Emphasis are applicable to each award mechanism offered by the FY17 NFRP.  If the proposed research project does not address one of the FY17 Areas of Emphasis, justification that the proposed research project addresses an important problem related to NF research and/or patient care should be provided.

Health services research

  • Evidence-based clinical care pathways
  • Innovative healthcare delivery systems
  • Utilization of technology and informatics

Heterogeneity of neurofibromas and other NF-related tumors

Nontumor manifestations

  • Sleep, pain, hypotonia, communication, etc., including quality of life measures, self-reported and otherwise

Novel disease and treatment response markers using genomics, epigenetics, systems biology, metabolomics, or similar approaches

  • Transition from benign to malignant

Nutritional, environmental, and other modifiers of NF

Post-adolescent manifestations

Preclinical efficacy studies

Target identification, drug discovery, targeted and immunotherapies

Other

Clinical Trial Award – Letter of Intent due Jul7 26, 2017

  • Independent investigators at or above the level of Assistant Professor (or equivalent)
  • Fund Phase 0, I, or II clinical trials relevant to NF and/or schwannomatosis; combinations of phases are permitted.
  • Funding must support a clinical trial and may not be used for preclinical studies.
  • Scientific rationale and preliminary data required for Phase I, II clinical trial applications.
  • Maximum funding of $900,000 for direct costs (plus indirect costs)
  • Maximum period of performance is years

Exploration – Hypothesis Development Award – Letter of Intent due July 26, 2017

  • All academic levels (or equivalent)
  • Fund the initial exploration of innovative, high-risk, high-gain and potentially. groundbreaking concepts in NF research
  • Projects involving human subjects or human biological substances must be exempt under 32 CFR 219.101(b) or eligible for expedited review under 32 CFR 219.110 or 21 CFR 56.110.
  • Preliminary and/or published data is encouraged but not required.
  • Clinical trials not allowed
  • Maximum funding of $100,000 for direct costs (plus indirect costs)
  • Maximum period of performance is 2 years

 

Investigator-Initiated Research Award – Letter of Intent due July 26, 2017

  • Independent investigators at or above the level of Assistant Professor (or equivalent)
  • Fund highly rigorous, high-impact research projects that have the potential to make an important contribution to NF research and/or patient care.
  • Optional Feature: Applications that include a Qualified Collaborator who meets criteria identified in the announcement may apply for a higher level of funding.
  • Preliminary and/or published data required.
  • Clinical trials not allowed.
  • Maximum funding of $525,000 for direct costs (plus indirect costs)
  • Maximum funding of $575,000 for direct costs (plus indirect costs) for applications including an Optional Qualified Collaborator
  • Maximum period of performance is 3years

 

New Investigator Award – Letter of Intent due July 26, 2017

  • Independent investigators at or below the level of Assistant Professor (or equivalent) or an established investigator at or above the level of Assistant Professor seeking to transition into a career in NF research
  • Support the continued development of promising independent investigators and/or the transition of established investigators into a career in the field of NF research
  • Experience in NF research is allowed, but not required
  • Preliminary and/or published data required
  • Clinical trials not allowed
  • Maximum funding of $450,000 for direct costs (plus indirect costs)
  • Maximum period of performance is 3 years

 

A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline. All applications must conform to the final Program Announcements and General Application Instructions available for electronic downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism will also be found on Grants.gov.  A listing of all CDMRP funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420.

 

Applications must be submitted through the federal government’s single-entry portal, Grants.gov.  For email notification when Program Announcements are released go to the CDMRP website (http://cdmrp.army.mil) and select Subscribe to Funding Opportunities & Program Communications.  For more information about the NFRP or other CDMRP-administered programs, please visit the CDMRP website (http://cdmrp.army.mil).

Point of Contact:

CDMRP Help Desk

301-682-5507

help@eBrap.org